| Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes E Pleasance, E Titmuss, L Williamson, H Kwan, L Culibrk, EY Zhao, ... Nature Cancer 1 (4), 452-468, 2020 | 149 | 2020 |
| Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study SG Morgan, J Hunt, J Rioux, J Proulx, D Weymann, C Tannenbaum Canadian Medical Association Open Access Journal 4 (2), E346-E351, 2016 | 149 | 2016 |
| Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults SG Morgan, D Weymann, B Pratt, K Smolina, EJ Gladstone, C Raymond, ... Age and ageing 45 (4), 535-542, 2016 | 99 | 2016 |
| Whole-genome and transcriptome analysis enhances precision cancer treatment options E Pleasance, A Bohm, LM Williamson, JMT Nelson, Y Shen, M Bonakdar, ... Annals of oncology 33 (9), 939-949, 2022 | 87 | 2022 |
| Postmarket policy considerations for biosimilar oncology drugs MJ Renwick, K Smolina, EJ Gladstone, D Weymann, SG Morgan The Lancet Oncology 17 (1), e31-e38, 2016 | 75 | 2016 |
| Valuation of health and nonhealth outcomes from next-generation sequencing: approaches, challenges, and solutions DA Regier, D Weymann, J Buchanan, DA Marshall, S Wordsworth Value in Health 21 (9), 1043-1047, 2018 | 70 | 2018 |
| The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers D Weymann, J Laskin, R Roscoe, KA Schrader, S Chia, S Yip, ... Molecular genetics & genomic medicine 5 (3), 251-260, 2017 | 68 | 2017 |
| Geographic variations in prescription opioid dispensations and deaths among women and men in British Columbia, Canada EJ Gladstone, K Smolina, D Weymann, K Rutherford, SG Morgan Medical Care 53 (11), 954-959, 2015 | 39 | 2015 |
| Toward the diagnosis of rare childhood genetic diseases: what do parents value most? S Pollard, D Weymann, J Dunne, F Mayanloo, J Buckell, J Buchanan, ... European Journal of Human Genetics 29 (10), 1491-1501, 2021 | 36 | 2021 |
| Economic evaluations of next-generation precision oncology: a critical review D Weymann, R Pataky, DA Regier JCO Precision Oncology 2, 1-23, 2018 | 35 | 2018 |
| A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada DA Regier, S Pollard, M McPhail, T Bubela, TP Hanna, C Ho, HJ Lim, ... npj Precision Oncology 6 (1), 76, 2022 | 34 | 2022 |
| Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges D Weymann, N Dragojlovic, S Pollard, DA Regier Journal of community genetics 13 (5), 467-476, 2022 | 29 | 2022 |
| Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication S Pollard, S Kalloger, D Weymann, S Sun, J Nuk, KA Schrader, DA Regier Health Expectations 23 (4), 884-892, 2020 | 27 | 2020 |
| Long-term sedative use among community-dwelling adults: a population-based analysis D Weymann, EJ Gladstone, K Smolina, SG Morgan Canadian Medical Association Open Access Journal 5 (1), E52-E60, 2017 | 26 | 2017 |
| Matching methods in precision oncology: an introduction and illustrative example D Weymann, J Laskin, SJM Jones, H Lim, DJ Renouf, R Roscoe, ... Molecular Genetics & Genomic Medicine 9 (1), e1554, 2021 | 24 | 2021 |
| Having our “omic” cake and eating it too?: evaluating user response to using Blockchain technology for private and secure health data management and sharing VL Lemieux, D Hofman, H Hamouda, D Batista, R Kaur, W Pan, ... Frontiers in Blockchain 3, 558705, 2021 | 23 | 2021 |
| Defining a core data set for the economic evaluation of precision oncology S Pollard, D Weymann, B Chan, M Ehman, S Wordsworth, J Buchanan, ... Value in Health 25 (8), 1371-1380, 2022 | 20 | 2022 |
| Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment D Weymann, DL Veenstra, GP Jarvik, DA Regier European Journal of Human Genetics 26 (9), 1257-1265, 2018 | 18 | 2018 |
| High‐Cost Users of Prescription Drugs: A Population‐Based Analysis from British Columbia, Canada D Weymann, K Smolina, EJ Gladstone, SG Morgan Health services research 52 (2), 697-719, 2017 | 18 | 2017 |
| Clinical and cost outcomes following genomics‐informed treatment for advanced cancers D Weymann, S Pollard, B Chan, E Titmuss, A Bohm, J Laskin, SJM Jones, ... Cancer Medicine 10 (15), 5131-5140, 2021 | 17 | 2021 |
